Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 24, 2026, 2:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 337–360 of 1,868 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: DEXAMETHASONE Clear all
Terminated Phase 2 Interventional Results available

VELCADE,Rituximab,Cyclophosphamide and Decadron

NCT00413959
View directory record Official record
Conditions
Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
Interventions
VELCADE®, Rituximab, Cyclophosphamide, Decadron
Drug
Lead sponsor
Oncology Specialists, S.C.
Other
Eligibility
18 Years to 90 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
2
States / cities
Niles, Illinois • Park Ridge, Illinois
Source: ClinicalTrials.gov public record
Updated Sep 19, 2018 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Safety, Tolerability and Pharmacokinetics Study of KPG-818 in Hematological Malignancies Subjects

NCT04283097
View directory record Official record
Conditions
Hematological Malignancies
Interventions
KPG-818
Drug
Lead sponsor
Kangpu Biopharmaceuticals, Ltd.
Industry
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2024
U.S. locations
10
States / cities
Sacramento, California • Plantation, Florida • Louisville, Kentucky + 7 more
Source: ClinicalTrials.gov public record
Updated May 16, 2025 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy of an Intravitreal DEX Implant in Retinal Vein Occlusion Following Treatment With Anti-VEGF Injections.

NCT01449682
View directory record Official record
Conditions
Retinal Vein Occlusion, Macular Edema
Interventions
Ozurdex
Drug
Lead sponsor
Retina Macula Institute
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2013
U.S. locations
1
States / cities
Torrance, California
Source: ClinicalTrials.gov public record
Updated May 31, 2017 · Synced Oct 24, 2026, 2:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

NCT04140162
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Daratumumab, Lenalidomide, Bortezomib, Dexamethasone
Drug
Lead sponsor
University of Michigan Rogel Cancer Center
Other
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
4
States / cities
Ann Arbor, Michigan • Detroit, Michigan • Rochester, New York + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 28, 2026 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Daratumumab (HuMax®-CD38) Safety Study in Multiple Myeloma

NCT00574288
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Part 1: Daratumumab, Part 2: Daratumumab, Methylprednisolone, Dexamethasone
Drug · Other
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
104 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2017
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 27, 2018 · Synced Oct 24, 2026, 2:57 AM EDT
Active, not recruiting Phase 2 Interventional Results available

A Phase II Study of Daratumumab, Clarithromycin, Pomalidomide And Dexamethasone (D-ClaPd) In Multiple Myeloma Patients Previously Exposed to Daratumumab

NCT04302324
View directory record Official record
Conditions
Multiple Myeloma, Refractory Multiple Myeloma, Relapse Multiple Myeloma
Interventions
Daratumumab SC, Clarithromycin, Pomalidomide, Dexamethasone
Drug
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
18 Years to 75 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 20, 2026 · Synced Oct 24, 2026, 2:57 AM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

Exparel vs Block for ACL Reconstruction

NCT06006624
View directory record Official record
Conditions
ACL, Postoperative Pain
Interventions
Exparel 30 mL, 0.5% bupivacaine, Dexamethasone, iPACK block
Drug
Lead sponsor
Rothman Institute Orthopaedics
Other
Eligibility
18 Years and older
Enrollment
154 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 21, 2024 · Synced Oct 24, 2026, 2:57 AM EDT
Terminated Phase 2Phase 3 Interventional Accepts healthy volunteers Results available

Dose Escalation of Dexamethasone to Increase Duration of Transversus Abdominal Plane Block Following Cesarean Section

NCT03098420
View directory record Official record
Conditions
Post Surgical Pain
Interventions
2mg Dexamethasone, 4mg Dexamethasone, Ropivacaine (TAP blocks), Morphine, Bupivacaine Hydrochloride, Normal saline 1ml, Normal saline 0.5ml
Drug
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2021
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jun 18, 2021 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Dexamethasone Dyspnea Study

NCT01670097
View directory record Official record
Conditions
Advanced Cancers, Hematologic Disorder, Solid Tumors
Interventions
Dexamethasone, Placebo, Questionnaires, Spirometer, Phone Calls
Drug · Behavioral · Device + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
52 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 17, 2021 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

The Adrenal Contribution to Androgen Production in Girls During Puberty

NCT01062568
View directory record Official record
Conditions
Development
Interventions
Adrenocorticotropin, Dexamethasone
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 18 Years · Female only
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Abiraterone Acetate Dose-Escalation Study in Hormone Refractory Prostate Cancer

NCT00473746
View directory record Official record
Conditions
Prostate Neoplasms
Interventions
Abiraterone acetate, prednisone/prednisolone or dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Male only
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
3
States / cities
San Francisco, California • Boston, Massachusetts • Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 29, 2014 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

NCT00884546
View directory record Official record
Conditions
Advanced Cancer, Various, NOS
Interventions
BMS-833923, Lenalidomide, Dexamethasone, Bortezomib
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
27 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
8
States / cities
Duarte, California • La Jolla, California • Los Angeles, California + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2016 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Not applicable Interventional Results available

Cortisol Suppression and Startle Responses in Posttraumatic Stress Disorder (PTSD)

NCT01477762
View directory record Official record
Conditions
Post Traumatic Stress Disorder
Interventions
Dexamethasone, Placebo
Drug
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
165 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 24, 2026, 2:57 AM EDT
Terminated Phase 2 Interventional

Phase 2 Trial of AEZS-108 in Chemotherapy Refractory in Triple Negative Breast Cancer

NCT01698281
View directory record Official record
Conditions
Breast Cancer
Interventions
AEZS-108, SCCC, Dexamethasone
Drug
Lead sponsor
AEterna Zentaris
Industry
Eligibility
18 Years and older · Female only
Enrollment
7 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Feb 22, 2018 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 1 Interventional

A Study of DKN-01 and Lenalidomide/Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

NCT01711671
View directory record Official record
Conditions
Multiple Myeloma
Interventions
DKN-01 300 mg, DKN-01 600 mg, Standard of Care
Drug
Lead sponsor
Leap Therapeutics, Inc.
Industry
Eligibility
30 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Atlanta, Georgia • Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 3, 2025 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 2 Interventional

FST-100 in the Treatment of Acute Adenoviral Conjunctivitis

NCT01470664
View directory record Official record
Conditions
Acute Adenoviral Conjunctivitis
Interventions
FST-100, FST-100 (Component #1), FST-100 Vehicle
Drug
Lead sponsor
Shire
Industry
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jun 25, 2021 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 3 Interventional

Dexamethasone With or Without Thalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma

NCT00033332
View directory record Official record
Conditions
Multiple Myeloma and Plasma Cell Neoplasm
Interventions
dexamethasone, pamidronate disodium, thalidomide, zoledronic acid
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2006
U.S. locations
75
States / cities
Scottsdale, Arizona • Duarte, California • Palo Alto, California + 55 more
Source: ClinicalTrials.gov public record
Updated Apr 4, 2014 · Synced Oct 24, 2026, 2:57 AM EDT
Recruiting Phase 4 Interventional

Buprenorphine, Clonidine, and Dexamethasone on Duration of Brachial Plexus Blocks for Upper Extremity Surgery

NCT05824832
View directory record Official record
Conditions
Pain, Postoperative
Interventions
Interscalene block with the addition of buprenorphine, clonidine, dexamethasone, Interscalene block with buprenorphine alone
Drug
Lead sponsor
Loyola University
Other
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Maywood, Illinois
Source: ClinicalTrials.gov public record
Updated Mar 7, 2025 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 3 Interventional Results available

A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

NCT03201965
View directory record Official record
Conditions
Amyloidosis
Interventions
Cyclophosphamide, Bortezomib, Dexamethasone, 40 mg, Daratumumab
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older
Enrollment
416 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2024
U.S. locations
29
States / cities
Phoenix, Arizona • Duarte, California • San Francisco, California + 22 more
Source: ClinicalTrials.gov public record
Updated Nov 26, 2025 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 2 Interventional Results available

Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell Lymphomas

NCT00783367
View directory record Official record
Conditions
Follicular Lymphoma, Marginal Zone B-Cell Lymphoma, MALT Lymphoma, Lymphoma of Mucosa-Associated Lymphoid Tissue, Lymphoma, Small Lymphocytic, Waldenstrom Macroglobulinemia, Mantle-Cell Lymphoma
Interventions
Lenalidomide, Dexamethasone, Rituximab
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 30, 2023 · Synced Oct 24, 2026, 2:57 AM EDT
Recruiting Phase 2 Interventional

Isa-Rd for Frail and/or Much Older Patients With Newly Diagnosed Multiple Myeloma

NCT05145400
View directory record Official record
Conditions
Multiple Myeloma, Cancer
Interventions
Isatuximab, Lenalidomide, Dexamethasone
Drug
Lead sponsor
UNC Lineberger Comprehensive Cancer Center
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2033
U.S. locations
5
States / cities
Chapel Hill, North Carolina • Charlotte, North Carolina • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Jun 2, 2026 · Synced Oct 24, 2026, 2:57 AM EDT
Active, not recruiting Phase 1 Interventional

MC210808 Venetoclax in Combination With Lenalidomide and Dexamethasone (Ven-Rd), Daratumumab and Dexamethasone (Ven-Dd), or Daratumumab-Lenalidomide-Dexamethasone (Ven-DRd) for the Treatment of Multiple Myeloma

NCT06042725
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Chest Radiography, Computed Tomography, Daratumumab, Dexamethasone, Lenalidomide, Low Dose Computed Tomography of the Whole Body, Magnetic Resonance Imaging, Positron Emission Tomography, Venetoclax, X-Ray Imaging, Questionnaire Administration
Procedure · Biological · Drug + 1 more
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Oct 24, 2026, 2:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Cyclophosphamide, Carfilzomib, Thalidomide, and Dexamethasone in Treating Patients With Newly Diagnosed Active Multiple Myeloma

NCT01057225
View directory record Official record
Conditions
Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
Interventions
carfilzomib, cyclophosphamide, thalidomide, dexamethasone
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2017
U.S. locations
3
States / cities
Scottsdale, Arizona • Rochester, Minnesota • Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Dec 12, 2017 · Synced Oct 24, 2026, 2:57 AM EDT
Active, not recruiting Phase 2 Interventional

Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

NCT04329325
View directory record Official record
Conditions
Acute Lymphoblastic Leukemia, Philadelphia Chromosome-Positive
Interventions
Blinatumomab, dasatinib, dexamethasone, methotrexate
Biological · Drug
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 7, 2026 · Synced Oct 24, 2026, 2:57 AM EDT